Preferred frequencies and waveforms for spinal cord stimulation in patients with complex regional pain syndrome: A multicentre, double-blind, randomized and placebo-controlled crossover trial

被引:99
作者
Kriek, N. [1 ]
Groeneweg, J. G. [1 ]
Stronks, D. L. [1 ]
de Ridder, D. [2 ]
Huygen, F. J. P. M. [1 ]
机构
[1] Erasmus MC Univ Med Ctr Rotterdam, Ctr Pain Med, Rotterdam, Netherlands
[2] Univ Otago, Dunedin Sch Med, Sect Neurosurg, Dept Surg Sci, Dunedin, New Zealand
关键词
BACK SURGERY SYNDROME; CONVENTIONAL MEDICAL-MANAGEMENT; ELECTRICAL INHIBITION; LIMB; MECHANISMS;
D O I
10.1002/ejp.944
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Conventional tonic spinal cord stimulation (SCS) is an effective treatment for patients with therapy-resistant complex regional pain syndrome (CRPS). Although the therapeutic effect of SCS can diminish over time due to tolerance, pain control can be regained by changing the pulse width and the amplitude and/or by increasing the stimulation frequency. This multicentre, double-blind, randomized and placebo-controlled crossover trial was conducted to investigate whether more effective pain reduction is achieved with different frequencies (trial registration, current controlled trials, ISRCTN 36655259). Methods: The investigated settings are as follows: standard 40, 500, 1200 Hz, burst and placebo stimulation. All five were programmed in random order during the 10-week crossover period (2 weeks/setting). The primary outcome parameters were scores on the visual analogue scale (VAS), McGill Pain Questionnaire (MPQ) and the Global Perceived Effect (GPE); at the end of the crossover period, patients decided which SCS setting they preferred. A linear mixed models analysis was performed in 29 patients who completed the crossover trial. Results: Significant pain reduction and GPE satisfaction was achieved with four SCS settings compared with placebo stimulation, and these four settings did not differ significantly from each other. Standard stimulation was preferred by 48% of the patients, while 52% preferred non-standard stimulation. Other than pain reduction, factors such as user-friendliness, comfort and recharging time may have influenced the patient's final decision for the preferred stimulation setting. Conclusions: Apparently, for various reasons, patients have a preference for different SCS setting. Therefore, future neuromodulation should aim to implement customized individual patient care by incorporating all stimulation options in one device. Significance: This study demonstrates that standard frequency SCS is an effective therapy for patients with CRPS. However, it also demonstrates that patients can often gain better pain reduction with non-standard frequencies of SCS. Furthermore, it shows that the preferred stimulation setting is not solely driven by the amount of pain reduction, but is also influenced by which stimulation setting feels most comfortable and provides the best user-friendliness. Therefore, we strive to maximize the therapeutic effects of SCS in as many patients as possible. This can be achieved with customized individual patient care by incorporating the various frequencies and waveforms into one single device.
引用
收藏
页码:507 / 519
页数:13
相关论文
共 50 条
  • [21] No effect of a pulsed magnetic field on induced ischemic muscle pain. A double-blind, randomized, placebo-controlled trial
    Szemerszky, Renata
    Szabolcs, Zsuzsanna
    Bogdany, Tamas
    Janossy, Gabor
    Thuroczy, Gyorgy
    Koteles, Ferenc
    PHYSIOLOGY & BEHAVIOR, 2018, 184 : 55 - 59
  • [22] Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
    Roohi-Azizi, Mahtab
    Arabzadeh, Somaye
    Amidfar, Meysam
    Salimi, Samrand
    Zarindast, Mohammad Reza
    Talaei, Ali
    Akhondzadeh, Shahin
    CLINICAL NEUROPHARMACOLOGY, 2017, 40 (01) : 1 - 5
  • [23] Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial
    Sola Martinez, Francisco Javier
    Barranco Jimenez, Ruth Maria
    Martin Garcia, Cristina
    Senent Sanchez, Carlos
    Blanco Guerra, Carlos
    Fernandez-Rivas, Montserrat
    Vega Castro, Arantza
    Davila Gonzalez, Ignacio
    Carbonell Martinez, Antonio
    Panizo Bravo, Carmen
    Gomez Torrijos, Elisa
    Rodriguez Gil, David
    Palacios Pelaez, Ricardo
    CLINICAL AND EXPERIMENTAL ALLERGY, 2020, 50 (12) : 1352 - 1361
  • [24] A randomized, double-blind, placebo-controlled trial with mannan-conjugated birch pollen allergoids
    Moesges, Ralph
    Zeyen, Christoph
    Raskopf, Esther
    Acikel, Cengizhan
    Sahin, Hacer
    Allekotte, Silke
    Cuevas, Mandy
    Shamji, Mohamed H.
    Subiza, Jose Luis
    Casanovas, Miguel
    ALLERGY, 2024, 79 (04) : 990 - 1000
  • [25] A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome
    Hess, Laura Greiss
    Fitzpatrick, Sarah E.
    Nguyen, Danh V.
    Chen, Yanjun
    Gaul, Kimberly N.
    Schneider, Andrea
    Chitwood, Kerrie Lemons
    Eldeeb, Marwa Abd Al Azaim
    Polussa, Jonathan
    Hessl, David
    Rivera, Susan
    Hagerman, Randi J.
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2016, 37 (08) : 619 - 628
  • [26] Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double-blind, randomized, multicentre, placebo-controlled trial
    Meininger, Vincent
    Drory, Vivian E.
    Leigh, P. Nigel
    Ludolph, Albert
    Robberecht, Wim
    Silani, Vincenzo
    AMYOTROPHIC LATERAL SCLEROSIS, 2009, 10 (5-6): : 378 - U191
  • [27] Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study
    Rauck, R.
    North, J.
    Gever, L. N.
    Tagarro, I.
    Finn, A. L.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1308 - 1314
  • [28] Clinical Efficacy of Phosphodiesterase-5 Inhibitor Tadalafil in Eisenmenger Syndrome-A Randomized, Placebo-controlled, Double-blind Crossover Study
    Mukhopadhyay, Saibal
    Nathani, Srikanth
    Yusuf, Jamal
    Shrimal, Devendra
    Tyagi, Sanjay
    CONGENITAL HEART DISEASE, 2011, 6 (05) : 424 - 431
  • [29] Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome - a randomized, double-blind, placebo-controlled study
    Wittmann, T.
    Paradowski, L.
    Ducrotte, P.
    Bueno, L.
    Delestrain, M. -C. Andro
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (06) : 615 - 624
  • [30] A randomised, double-blind, placebo-controlled crossover trial of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model: an enriched population trial
    Lee, Michael C.
    Bond, Simon
    Wheeler, Daniel
    Scholtes, Ingrid
    Armstrong, Graham
    McNaughton, Peter
    Menon, David
    PAIN, 2019, 160 (11) : 2554 - 2565